Inactive Instrument

Immunomedics, Inc.

Equities

IMMU

US4529071080

Biotechnology & Medical Research

Immunomedics, Inc. Approves Board Appointments

March 03, 2017 at 12:00 pm EST

Immunomedics, Inc. at its Annual Meeting of stockholders held on March 3, 2017, elected all four of venBio Select Advisor LLC's independent, nominees – Scott Canute, Peter Barton Hutt, Dr. Khalid Islam, and Dr. Behzad Aghazadeh.

Latest news about Immunomedics, Inc.

Everest Medicines Limited announced that it has received $280 million in funding from Immunomedics, Inc.	23-03-26	CI
Gilead Sciences : Raises Product Sales Guidance on Remdesivir Demand, Narrows Earnings Outlook for 2020	21-01-11	DJ
Gilead Sciences : to Pay $1.4 Billion for Hepatitis Drug Maker MYR GmbH of Germany	20-12-10	DJ
Gilead Sciences : Quarterly Revenue Rises on Remdesivir Sales -- Update	20-10-28	DJ
Gilead Sciences : Quarterly Revenue Rises on Remdesivir Sales	20-10-28	DJ
Immunomedics, Inc. Announces Board Changes	20-10-23	CI
Immunomedics, Inc.(NasdaqGM:IMMU) dropped from S&P Biotechnology Select Industry Index	20-10-23	CI
Immunomedics, Inc.(NasdaqGM:IMMU) dropped from S&P Global BMI Index	20-10-23	CI
Immunomedics, Inc.(NasdaqGM:IMMU) dropped from S&P TMI Index	20-10-23	CI
Immunomedics, Inc.(NasdaqGM:IMMU) dropped from Russell 1000 Index	20-10-23	CI
Immunomedics, Inc.(NasdaqGM:IMMU) dropped from Russell Midcap Index	20-10-23	CI
Immunomedics, Inc.(NasdaqGM:IMMU) dropped from Russell 1000 Growth Index	20-10-23	CI
Immunomedics, Inc.(NasdaqGM:IMMU) dropped from Russell Midcap Growth Index	20-10-23	CI
Immunomedics, Inc.(NasdaqGM:IMMU) dropped from Russell 3000 Growth Index	20-10-23	CI
Immunomedics, Inc.(NasdaqGM:IMMU) dropped from Russell Small Cap Completeness Index	20-10-23	CI
Immunomedics, Inc.(NasdaqGM:IMMU) dropped from Russell 2500 Growth Index	20-10-23	CI
Immunomedics, Inc.(NasdaqGM:IMMU) dropped from Russell 3000 Index	20-10-23	CI
Immunomedics, Inc.(NasdaqGM:IMMU) dropped from Russell Small Cap Comp Growth Index	20-10-23	CI
Immunomedics, Inc.(NasdaqGM:IMMU) dropped from Russell 2500 Index	20-10-23	CI
Immunomedics, Inc.(NasdaqGM:IMMU) dropped from Russell 2500 Growth-Dynamic Index	20-10-23	CI
Immunomedics, Inc.(NasdaqGM:IMMU) dropped from Russell Midcap Gro-Dynamic Index	20-10-23	CI
Immunomedics, Inc.(NasdaqGM:IMMU) dropped from Russell Midcap Dynamic Index	20-10-23	CI
Immunomedics, Inc.(NasdaqGM:IMMU) dropped from Russell 2500 Dynamic Index	20-10-23	CI
Immunomedics, Inc.(NasdaqGM:IMMU) dropped from Russell 1000 Growth-Dynamic Index	20-10-23	CI
Immunomedics, Inc.(NasdaqGM:IMMU) dropped from Russell 1000 Dynamic Index	20-10-23	CI

Chart Immunomedics, Inc.

Duration

Period

More charts

Company Profile

Immunomedics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. It has a pipeline of six clinical-stage product candidates. Its portfolio of investigational products includes antibody-drug conjugates (ADCs) that are designed to deliver a payload of a chemotherapeutic directly to the tumor, while the managing overall toxic effects that are found with conventional administration of these chemotherapy agents. Its ADCs are sacituzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130). The Company also has a range of other product candidates that target solid tumors and hematologic malignancies, as well as other diseases, in various-stages of clinical and pre-clinical development.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+44.48%	55.07B
LONZA GROUP AG	+43.85%	40.22B
IQVIA HOLDINGS INC.	-0.86%	41.79B
CELLTRION, INC.	-7.59%	28.17B
ICON PUBLIC LIMITED COMPANY	+12.30%	26.28B
ALNYLAM PHARMACEUTICALS, INC.	-21.83%	18.93B
BIO-TECHNE CORPORATION	+7.15%	13.03B
MEDPACE HOLDINGS, INC.	+29.40%	12.26B
UNITED THERAPEUTICS CORPORATION	+25.15%	12.21B

Other Biotechnology & Medical Research